News

Recent KeyPlants News

The Virtual American Biomanufacturing Summit

Meet KeyPlants at The Virtual American Biomanufacturing Summit, April 27-29

KeyPlants will be sponsoring the Virtual American Biomanufacturing Summit on April 27-29. At the conference, a lunch-and-learn about modular biomanufacturing facilities will be led by Pär Almhem, KeyPlants’ Director of Business Development in North America. David Lindholm, KeyPlants’ Head of Sales will also be attending the conference.

KeyPlants lunch-and-learn session at the conference

Rapid and Cost Effective Deployment of Modular Biomanufacturing Facilities

Discussion about using modular construction to fast and efficiently build new pharma and biotech production capacity. Topics to discuss:

  • What is “modular” and “off-site” construction and why should we use it?
  • What are the options to use modular – when and how to use them?
  • What do end users want from a modular approach and what are their concerns?

For more information about the event, see https://biomanamerica.com/

Connect with us to learn about KeyPlants’ modular concept and how it helps our customers to rapidly deploy manufacturing capacity worldwide.

American Biomanufacturing Summit

Webinar – Process Simulation and Scheduling – Valuable tools for design of biopharmaceutical facilities

Live Webinar April 28 at 3pm – 4pm CET

Learn about the benefits of process simulation and scheduling  tools for debottlenecking, capacity increase and design of biopharmaceutical facilities. Gain a better understanding of SuperPro Designer and SchedulePro through actual case studies.

Sign up: https://lnkd.in/ecRKMqh

Questions? Please send an email to [email protected]

Welcome to join this free Webinar!

 

Agenda

The role of process simulation and scheduling tools in the biopharmaceutical industries with emphasis on cycle time reduction, debottlenecking, utility system sizing and multi-product facility design.

Demetri Petrides, President, Intelligen, Inc.

Learn from KeyPlants experience and case studies about capital investment projects in the biomanufacturing industry. How to use scheduling tools:

  • Facility design based on process modelling
  • Identify existing bottlenecks to increase capacity
  • Provide insights for capital investment decisions
  • Validate feasibility of a developed design concept

Ted Witherow, Process Engineer, KeyPlants

KeyPlants will be attending and presenting at New Horizons in Biologics & Bioprocessing

The need for more capacity to produce vaccines has increased since the COVID-19 outbreak. Global manufacturing trends are changing, and trends started years ago are being accelerated. There is a market demand to establish new vaccine facilities with speed, flexibility and predictability. This will be discussed as well as consequences on facility design based on manufacturing technology.

KeyPlants will be participating at New Horizons in Biologics & Bioprocessing on December 17th. At the event, David Lindholm will be talking about rapid deployment of vaccine facilities.

This digital event is free of charge. Registration and conference programme at http://www.bioprocessing.se/arrangement/page.xhtml?arrangeSubpage=489

Join and listen to KeyPlants’ presentation if you’re interested in this topic. It is possible to register and listen to the recorded version of the presentation also after December 17, after registration.

New horizons

Ziccum – Keyplants – new pilot study of cost-effective vaccine plant

Ziccum KeyplantsPRESS RELEASE ONE

 

ZICCUM takes lead on new pilot study of vaccine plant producing cost-effective thermostable vaccines at volume with KeyPlants as engineering partner 

Ziccum has produced a pilot study, including blueprints and costings, exploring the technical and financial viability of a Fill and Finish plant producing thermostable air-dried vaccines at volume. The plan, produced in collaboration with leading modular plant construction specialist KeyPlants AB, indicates significant financial benefits from formulating and packaging vaccines based on Ziccum’s LaminarPace ambient dry-formulation technology. Ziccum will now move forward and seek strategic partnerships for establishing a pilot plant for vaccine manufacturing.

One of Ziccum’s key strategic goals has always been the integration of its dry-formulation technology LaminarPace into large-scale vaccine manufacturing – as demonstrated by recent patent applications on key technical aspects of its technology. Ziccum CEO Göran Conradson: “We have long stated our commitment to integrating LaminarPace into an industrial GMP environment. The detailed project planning we have carried out with KeyPlants has clarified for us the enormous scale of the savings our technology offers over today’s standard lyophilization processes, and how achievable the concept is as well. With KeyPlants we have a partner with high expertise not only in pharmaceutical facility design and engineering, but also in vaccine production and aseptic processing solutions. The core and modular technology for these new facilities is already available, and the limitations of our present vaccine supply chain are clear. The need to increase global vaccine manufacturing volume and coverage, and to make it more affordable, is urgent. This is a historic opportunity.”

Ziccum AB’s air-drying technology transforms liquid vaccine solutions into thermostable dry powders. Unlike currently available commercial vaccines and vaccines in development, these dry powder vaccines can be stored and transported at ambient temperatures for extended periods. They require no Cold Chain and meet WHO CTC (Controlled Temperature Chain) requirements.

Ziccum has identified ‘Fill and Finish’ (F/F), the third and final stage of vaccine production, where medical vials are filled with vaccine solutions and packaged for distribution, as a key target area of vaccine production that would profit from Ziccum capabilities. The vast majority of today’s F/F plants formulate, store and pack vaccines as liquid or lyophilized (freeze-dried) solutions – both are complex, costly, energy-intensive processes compared to ambient air drying.

Together with KeyPlants AB, a global leader in agile modular solutions who have carried out more than 50 projects globally, including F/F vaccine facilities, Ziccum has now drawn up detailed blueprints for a 36 m x 27 m two-floor F/F plant that would be able to produce up to 30 million doses of dry-formulated vaccine a year at an estimated 65% lower OPEX cost and 50% lower CAPEX cost than today’s standard lyophilization F/F plants. The pilot study report is attracting interest from some leading vaccine industry peers.

David Lindholm, head of Sales at KeyPlants: “We currently see a strong demand for new vaccine facilities and we’re currently working on several vaccine projects for customers worldwide. At KeyPlants we’re proud to be a key partner to Ziccum and we see great benefits with their LAPA-technology. This technology will not only significantly reduce facility CAPEX- and OPEX-costs, but also increase vaccine access and safety through the removal of the cold chain distribution.”

Ziccum CEO Göran Conradson: “We have made great progress with our other two key strategy areas – growing our IP portfolio of dry-formulated vaccines for license, and increasing our collaborations with vaccine research and stakeholder groups – we absolutely intend to keep developing those. Now, with the scale of potential savings revealed by our pilot study, we are focusing on building new collaborations and strategic partnerships to unlock funding and investment and move ahead towards capturing this extraordinary opportunity.   

“Our roots are in dry-powder aerosol technology, bringing the benefits of dry-formulation to vaccines could benefit millions around the world. We all consume essential food and pharma products in dry form as standard every day – knowing it means they can be stored and transported to more people, more cost-effectively. So why can’t we do the same with vaccines? The fact is we can. Now is the time for realistic new solutions for vaccine distribution. As an industry, we need to look again at what’s possible.”

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: [email protected]
Mobile: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

For more information about KeyPlants, please contact:

David Lindholm: Head of Sales KeyPlants AB
E-mail: [email protected]
Mobile: +46 703 295 868

About KeyPlants

KeyPlants provides fast track process and facility solutions for the Life Science and Advanced Technology Industries. KeyPlants is a global leader in modular facility solutions, having executed more than 50 modular projects globally. Pharmaceutical manufacturers around the world benefit from their modular off-site construction. Headquartered in Stockholm, Sweden, KeyPlants also provide engineering solutions and execute conventional pharmaceutical facility projects in the Nordic countries. Capabilities include full in-house design and construction as well as Subject Matter Expertise in Biomanufacturing, Aseptic Filling, Containment and Manufacturing of APIs and Oral Solids.

 

 

This press release has jointly been submitted for publication by the company’s CEO’s at 08.00 (CET) on October 16, 2020.